Methylphenidate facilitates and disinhibits the motor cortex in intact humans

NeuroReport

Volumn 14, Issue 5, 2003, Pages 773-776

  Ilić, Tihomir V ^a   Korchounov, Alexei ^a   Ziemann, Ulf ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Human; Methylphenidate; Motor cortex excitability; Motor evoked potential; Norepinephrine; Short interval intracortical inhibition and facilitation; Transcranial magnetic stimulation

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; METHYLPHENIDATE; NORADRENALIN;

ADULT; ARTICLE; CONTROLLED STUDY; EVOKED MUSCLE RESPONSE; FACILITATION; HAND MUSCLE; HUMAN; HUMAN EXPERIMENT; MOTOR CORTEX; NERVE CELL EXCITABILITY; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT; TRANSCRANIAL MAGNETIC STIMULATION;

ADULT; ANALYSIS OF VARIANCE; CENTRAL NERVOUS SYSTEM STIMULANTS; ELECTRIC STIMULATION; ELECTROMAGNETIC FIELDS; ELECTROPHYSIOLOGY; EVOKED POTENTIALS, MOTOR; HUMANS; MAGNETICS; METHYLPHENIDATE; MOTOR CORTEX; NEURAL INHIBITION; NOREPINEPHRINE; REFERENCE VALUES;

EID: 0038404614     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200304150-00023     Document Type: Article

References (25)

1. Feeney DM and Sutton RL. Crit Rev Neurobiol 3, 135-197 (1987).
2. Goldstein LB. Arch Neurol 55, 454-456 (1998).
3. Kline AE, Chen MJ, Tso-Olivas DY et al. Pharmacol Biochem Behav 48, 773-779 (1994).
4. Grade C, Redford B, Chrostowski J et al. Arch Phys Med Rehabil 79, 1047-1050 (1998).
5. McCormick DA and Williamson A. Proc Natl Acad Sci USA 86, 8098-8102 (1989).
6. Ziemann U and Hallett M. Basic neurophysiological studies with TMS. In: George MS and Belmaker RH (eds). Transcranial Magnetic Stimulation in Neuropsychiatry. Washington, DC: American Psychiatry Press; 2000, pp. 45-98.
7. Boroojerdi B, Battaglia F, Muellbacher W et al. Clin Neurophysiol 112, 931-937 (2001).
8. Herwig U, Bräuer K, Connemann B et al. Psychopharmacology 164, 228-232 (2002).
9. Plewnia C, Hoppe J, Hiemke C et al. Neurosci Lett 330, 231-234 (2002).
10. Plewnia C, Bartels M, Cohen L et al. Neurosci Lett 307, 41-44 (2001).
11. Garvey MA, Ziemann U, Becker DA et al. Clin Neurophysiol 112, 1451-1460 (2001).
12. Kujirai T, Caramia MD, Rothwell JC et al. J Physiol (Lond) 471, 501-519 (1993).
13. Ziemann U, Tergau F, Wischer S et al. Electroencephalogr Clin Neurophysiol 109, 321-330 (1998).
14. Hoffman BB and Lefkowitz RJ. Catecholamines, synapatomimetic drugs, and adrenergic receptor antagonists. In: Goodman Gilman A (ed.). The Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 1996, pp. 199-248.
15. Kuczenski R and Segal DS. J Pharmacol Exp Ther 296, 876-883 (2001).
16. Ziemann U, Bruns D and Paulus W. Neurosci Lett 208, 187-190 (1996).
17. Kasamatsu T and Heggelund P. Exp Brain Res 45, 317-327 (1982).
18. Foehring RC, Schwindt PC and Crill WE. J Neurophysiol 61, 245-256 (1989).
19. Bennett BD, Huguenard JR and Prince DA. J Neurophysiol 79, 937-946 (1998).
20. Bennett BD, Huguenard JR and Prince DA. J Neurophysiol 78, 561-566 (1997).
21. Werhahn KJ, Kunesch E, Noachtar S et al. J Physiol (Lond) 517, 591-597 (1999).
22. Kawaguchi Y and Shindou T. J Neurosci 18, 6963-6976 (1998).
23. Marek GJ and Aghajanian GK. Eur J Pharmacol 367, 197-206 (1999).
24. Moll GH, Heinrich H, Trott G et al. Neurosci Lett 284, 121-125 (2000).
25. Ziemann U, Muellbacher W, Hallett M et al. Brain 124, 1171-1181 (2001).